Publication Name	World Journal of Hepatology
Manuscript ID	73420
Country	Italy

Received	2021-11-25 18:28
Peer-Review Started	2021-11-25 18:30
To Make the First Decision
Return for Revision	2021-12-27 03:07
Revised	2022-01-11 11:31
Second Decision	2022-02-14 05:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-02-16 07:16
Articles in Press	2022-02-16 07:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-03-15 01:34
Publish the Manuscript Online	2022-03-24 14:13

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Safety of Direct Acting Antiviral treatment for hepatitis C in oncologic setting: a clinical experience and a literature review.
Manuscript Source	Invited Manuscript
All Author List	Anna Maria Spera
ORCID	Author(s) ORCID Number Anna Maria Spera http://orcid.org/0000-0003-1292-3040
Funding Agency and Grant Number
Corresponding Author	Anna Maria Spera, MD, PhD, Doctor, Doctor, Infectious Disease UNIT, Universitary Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona , Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it
Key Words	Hepatitis C Virus; DAAs; Drug interactions; Pharmacodynamic; Pharmacokinetic; Pre-emptive therapy
Core Tip	Chronic HCV infection is a hard clinical challenge, especially regarding oncologic patients eligible to chemotherapy. HCV reactivation in this setting of population is due to iatrogenic immunosuppression and can impair cancer treatment and outcome. Several specialists still do not prescribe direct aging antivirals to oncologic patients affected by HCV infection, because no univocal guidelines on HCV treatment in oncologic setting are available. The review highlights the importance of screening HCV infection before starting oncologic treatment, the safety of DAAs treatment under chemotherapy and the utility of treating HCV infection in oncologic setting no compromising chemotherapy course and success.
Publish Date	2022-03-24 14:13
Citation	Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 13(2): 525-534
URL	https://www.wjgnet.com//1948-5182/full/v14/i3/525.htm
DOI	https://dx.doi.org/10.4254/wjh.v14.i3.525

Full Article (PDF)	WJH-14-525.pdf
Full Article (Word)	WJH-14-525.docx
Manuscript File	73420_Auto_Edited-LJH.docx
Answering Reviewers	73420-Answering reviewers.pdf
Audio Core Tip	73420-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	73420-Conflict-of-interest statement.pdf
Copyright License Agreement	73420-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	73420-Language certificate.pdf
Peer-review Report	73420-Peer-review(s).pdf
Scientific Misconduct Check	73420-CrossCheck.jpg
Scientific Misconduct Check	73420-Bing-Liu JH-2.jpg
Scientific Editor Work List	73420-Scientific editor work list.pdf
CrossCheck Report	73420-CrossCheck report.pdf